Top News
Next Story

Sanofi India to sell its Ankleswar Facility to Zentiva for Rs.262 Cr Thomas Cook announces Grand India Holiday Sale, offers 100 free… L&T Oman bags a contract at Muscat TCS Partners with Cisco to Build Solutions that Accelerate… Glenmark Pharmaceuticals receives USFDA approval for Clobetasol…

Send Push
11th September, 2019 13:58 IST

Mumbai :  The Board of Directors of Sanofi India Limited (SIL) has approved a transaction for the slump sale and transfer of its manufacturing facility at Ankleshwar, Gujarat to Zentiva and its legal entity in India, Zentiva Private Limited for a consideration of Rs. 2,617 million ( 261.7 Crore), subject to customary working capital adjustments. This transaction is subject to shareholders’ approval and the completion of certain conditions as defined under the Business Transfer Agreement.

In 2018, as part of a global transaction, Zentiva, which was Sanofi’s European generics business, was sold to Advent International.

“Sanofi’s long-term strategy is to focus on manufacturing Sanofi branded products. Given that the two companies share similar values and commitment towards serving patients and their employees, the Board of Directors of Sanofi India Limited approved this transaction in the long-term interest of all stakeholders.” said Rajaram NARAYANAN, Managing Director – Sanofi India Limited.

The Ankleshwar site is Sanofi India’s oldest manufacturing facility where brands like Combiflam®, Allegra® and Amaryl® are made. The production of these iconic brands will now be moved to the Company’s Goa site and external manufacturing sites as well.

Explore more on Newspoint
Loving Newspoint? Download the app now